Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Viking Thera (VKTX)

Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,265,770
  • Shares Outstanding, K 111,436
  • Annual Sales, $ 0 K
  • Annual Income, $ -85,900 K
  • EBIT $ -134 M
  • EBITDA $ -142 M
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.71

Options Overview Details

View History
  • Implied Volatility 89.93% ( unch)
  • Historical Volatility 76.08%
  • IV Percentile 43%
  • IV Rank 38.27%
  • IV High 234.70% on 02/16/24
  • IV Low 0.20% on 02/27/24
  • Put/Call Vol Ratio 0.28
  • Today's Volume 4,347
  • Volume Avg (30-Day) 15,322
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 231,403
  • Open Int (30-Day) 209,883

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 12
  • High Estimate -0.22
  • Low Estimate -0.33
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -8.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.80 +3.30%
on 12/18/24
56.25 -30.58%
on 11/26/24
-12.46 (-24.19%)
since 11/19/24
3-Month
37.80 +3.30%
on 12/18/24
81.73 -52.22%
on 10/28/24
-29.11 (-42.71%)
since 09/19/24
52-Week
17.23 +126.63%
on 01/03/24
99.41 -60.72%
on 02/28/24
+19.90 (+103.91%)
since 12/19/23

Most Recent Stories

More News
Viking Therapeutics Stock Slides After Merck Strikes GLP-1 Deal With Chinese Biopharma, Retail Unperturbed

Viking’s own promising oral GLP-1 candidate, VK2735, is currently being studied for obesity and other metabolic conditions.

VKTX : 40.82 (+6.64%)
MRK : 98.74 (+0.41%)
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies...

VKTX : 40.82 (+6.64%)
VRTX : 387.20 (-13.47%)
LLY : 754.74 (-1.30%)
PFE : 25.91 (+0.08%)
Warning: This Skyrocketing Stock Has a Hidden Risk

One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the company reported solid results from trials of a candidate meant to address one of...

VKTX : 40.82 (+6.64%)
NVO : 103.18 (-2.62%)
LLY : 754.74 (-1.30%)
GS : 559.30 (+1.64%)
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

VKTX : 40.82 (+6.64%)
CRBP : 13.24 (-0.45%)
NVO : 103.18 (-2.62%)
$SPX : 5,890.68 (+0.32%)
LLY : 754.74 (-1.30%)
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?

Things aren't getting much better for Pfizer (NYSE: PFE) . The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it...

VKTX : 40.82 (+6.64%)
VRTX : 387.20 (-13.47%)
PFE : 25.91 (+0.08%)
After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?

There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (NASDAQ: VKTX), which...

VKTX : 40.82 (+6.64%)
LLY : 754.74 (-1.30%)
GS : 559.30 (+1.64%)
PFE : 25.91 (+0.08%)
2 Disruptive Growth Stocks With Room to Run

The investment landscape has transformed since the presidential election, with small-cap stocks gaining momentum. The Russell 2000 index, which tracks the performance of roughly 2,000 smaller publicly...

STLA : 12.95 (+1.09%)
VKTX : 40.82 (+6.64%)
ACHR : 8.58 (-4.13%)
MS : 122.24 (+0.99%)
JAPSY : 8.1200 (-1.34%)
Here's Yet Another Reason to Buy Viking Therapeutics Stock Like There's No Tomorrow

Viking Therapeutics (NASDAQ: VKTX) is a hot biotech stock thanks to the company's record of reporting good data from its cardiometabolic disease programs, and there's no sign of that reputation being tarnished....

VKTX : 40.82 (+6.64%)
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst

Ken Griffin started the Citadel hedge fund in 1990. It's become so successful that his net worth has risen to a stunning $46 billion.

VKTX : 40.82 (+6.64%)
RILY : 4.98 (+1.84%)
NVO : 103.18 (-2.62%)
MDGL : 296.83 (+1.39%)
LLY : 754.74 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

3rd Resistance Point 47.70
2nd Resistance Point 45.63
1st Resistance Point 41.95
Last Price 40.82
1st Support Level 36.20
2nd Support Level 34.13
3rd Support Level 30.45

See More

52-Week High 99.41
Fibonacci 61.8% 68.02
Fibonacci 50% 58.32
Fibonacci 38.2% 48.62
Last Price 40.82
52-Week Low 17.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar